You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for Patent: 8,765,167

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,765,167 protect, and when does it expire?

Patent 8,765,167 protects EXSERVAN, SYMPAZAN, and KYNMOBI, and is included in three NDAs.

This patent has one hundred and sixty-one patent family members in eighteen countries.

Summary for Patent: 8,765,167

Title:	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Abstract:	The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.
Inventor(s):	Myers; Garry L. (Kingsport, TN), Sanghvi; Pradeep (Schererville, IN), Verrall; Andrew Philip (Crown Point, IN), Francis; Vimala (Fremont, CA), Moss; Laura (Schererville, IN)
Assignee:	MonoSol Rx, LLC (Portage, IN)
Application Number:	11/517,982
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,765,167
Patent Claim Types: see list of patent claims	Compound; Process; Delivery;

Drugs Protected by US Patent 8,765,167

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Aquestive	EXSERVAN	riluzole	FILM;ORAL	212640-001	Nov 22, 2019		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Otter Pharms	SYMPAZAN	clobazam	FILM;ORAL	210833-001	Nov 1, 2018		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Otter Pharms	SYMPAZAN	clobazam	FILM;ORAL	210833-002	Nov 1, 2018		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
Otter Pharms	SYMPAZAN	clobazam	FILM;ORAL	210833-003	Nov 1, 2018		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,765,167

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077803	⤷ Sign Up
Austria	536868	⤷ Sign Up
Austria	536869	⤷ Sign Up
Austria	553746	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.